Related references
Note: Only part of the references are listed.Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor
Rong Hu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Chao Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis
Lina Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
Jaeki Min et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
PROTACs to address the challenges facing small molecule inhibitors
Pedro Martin-Acosta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Cancer Selective Target Degradation by Folate-Caged PROTACs
Jing Liu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer
Shipeng He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
PROTACs technology for targeting non-oncoproteins: Advances and perspectives
Chao Wang et al.
BIOORGANIC CHEMISTRY (2021)
Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants
Troy A. Bemis et al.
CHEMICAL COMMUNICATIONS (2021)
Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
Mohd Muddassir et al.
RSC ADVANCES (2021)
PHOTACs enable optical control of protein degradation
Martin Reynders et al.
SCIENCE ADVANCES (2020)
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative
Jian Zhang et al.
BIOORGANIC CHEMISTRY (2020)
Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications
Laura Goracci et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A caged E3 ligase ligand for PROTAC-mediated protein degradation with light
Cyrille S. Kounde et al.
CHEMICAL COMMUNICATIONS (2020)
Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
Nobumichi Ohoka et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
Michael L. Drummond et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2019)
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
William Farnaby et al.
NATURE CHEMICAL BIOLOGY (2019)
Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
Patrick Pfaff et al.
ACS CENTRAL SCIENCE (2019)
Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
Vittoria Zoppi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Blake E. Smith et al.
NATURE COMMUNICATIONS (2019)
SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
Michael J. Roy et al.
ACS CHEMICAL BIOLOGY (2019)
BET Proteins as Targets for Anticancer Treatment
Anastasios Stathis et al.
CANCER DISCOVERY (2018)
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
Sainan An et al.
EBIOMEDICINE (2018)
Bromodomain Drug Discovery - the Past, the Present, and the Future
Mehrosh Pervaiz et al.
CHEMICAL RECORD (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
Takao Fujisawa et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Waste disposal-An attractive strategy for cancer therapy
Jemilat Salami et al.
SCIENCE (2017)
Beyond the BET Family: Targeting CBP/p300 with 4-Acyl Pyrroles
Martin Huegle et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai et al.
CANCER RESEARCH (2017)
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
David Remillard et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Ana S. Leal et al.
CANCER LETTERS (2017)
Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC)
Geoffrey I. Shapiro et al.
MOLECULAR CANCER THERAPEUTICS (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor
Peter G. K. Clark et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Anastasia Wyce et al.
ONCOTARGET (2013)
Cancer and the bromodomains of BAF180
Peter M. Brownlee et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
ChromoHub: a data hub for navigators of chromatin-mediated signalling
Lihua Liu et al.
BIOINFORMATICS (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
Histone deacetylases and cancer
Bruna Barneda-Zahonero et al.
MOLECULAR ONCOLOGY (2012)
Targeting Epigenetic Readers in Cancer
Mark A. Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Reorganizing the protein space at the Universal Protein Resource (UniProt)
Rolf Apweiler et al.
NUCLEIC ACIDS RESEARCH (2012)
BET domain co-regulators in obesity, inflammation and cancer
Anna C. Belkina et al.
NATURE REVIEWS CANCER (2012)
The impact of epigenomics on future drug design and new therapies
Christopher A. Hamm et al.
DRUG DISCOVERY TODAY (2011)
Emerging roles of epigenetic mechanisms in Parkinson's disease
Ehsan Habibi et al.
FUNCTIONAL & INTEGRATIVE GENOMICS (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Share Paper
